COVID-19 Convalescent Plasma Therapy: Long-term Implications.
Autor: | Yoon H; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA., Li Y; Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA., Goldfeld KS; Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA., Cobb GF; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Sturm-Reganato CL; Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Ostrosky-Zeichner L; Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA., Jayaweera DT; Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.; Miami Clinical and Translational Science Institute, University of Miami Miller School of Medicine, Miami, Florida, USA., Philley JV; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Tyler, UTHealth East Texas, Tyler, Texas, USA., Desruisseaux MS; Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Keller MJ; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.; Harold and Muriel Block Institute for Clinical and Translational Research, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA., Hochman JS; Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA., Pirofski LA; Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.; Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA., Ortigoza MB; Division of Infectious Diseases, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.; Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Open forum infectious diseases [Open Forum Infect Dis] 2023 Dec 29; Vol. 11 (1), pp. ofad686. Date of Electronic Publication: 2023 Dec 29 (Print Publication: 2024). |
DOI: | 10.1093/ofid/ofad686 |
Abstrakt: | Background: The long-term effect of coronavirus disease 2019 (COVID-19) acute treatments on postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) is unknown. The CONTAIN-Extend study explores the long-term impact of COVID-19 convalescent plasma (CCP) therapy on postacute sequelae of SARS-CoV-2 infection (PASC) symptoms and general health 18 months following hospitalization. Methods: The CONTAIN-Extend study examined 281 participants from the original CONTAIN COVID-19 trial (CONTAIN-RCT, NCT04364737) at 18 months post-hospitalization for acute COVID-19. Symptom surveys, global health assessments, and biospecimen collection were performed from November 2021 to October 2022. Multivariable logistic and linear regression estimated associations between the randomization arms and self-reported symptoms and Patient-Reported Outcomes Measurement Information System (PROMIS) scores and adjusted for covariables, including age, sex, race/ethnicity, disease severity, and CONTAIN enrollment quarter and sites. Results: There were no differences in symptoms or PROMIS scores between CCP and placebo (adjusted odds ratio [aOR] of general symptoms, 0.95; 95% CI, 0.54-1.67). However, females (aOR, 3.01; 95% CI, 1.73-5.34), those 45-64 years (aOR, 2.55; 95% CI, 1.14-6.23), and April-June 2020 enrollees (aOR, 2.39; 95% CI, 1.10-5.19) were more likely to report general symptoms and have poorer PROMIS physical health scores than their respective reference groups. Hispanic participants (difference, -3.05; 95% CI, -5.82 to -0.27) and Black participants (-4.48; 95% CI, -7.94 to -1.02) had poorer PROMIS physical health than White participants. Conclusions: CCP demonstrated no lasting effect on PASC symptoms or overall health in comparison to the placebo. This study underscores the significance of demographic factors, including sex, age, and timing of acute infection, in influencing symptom reporting 18 months after acute hypoxic COVID-19 hospitalization. Competing Interests: Potential conflicts of interest. Ostrosky-Zeichner has received research grants and/or personal honoraria for consulting from Pfizer, Gilead Sciences, GlaxoSmithKline, Enanta, Quidel, and Viracor. Jayaweera has received research grants from NIH, Gilead Sciences, ViiV, ST-Pharma, and Janssen Pharmaceuticals. Jayaweera is a Consultant and Scientific Advisory Board Member for GlaxoSmithKline and ViiV pharmaceuticals. All other authors report no potential conflicts. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |